Differences in patient characteristics, disease-modifying treatment utilization, and relapse by race/ethnicity in Texas medicaid patients with multiple sclerosis

被引：0
|
作者：
Richards, K. M. [1 ]
Lawson, K. A. [1 ]
Nazareth, T. [2 ]
Yu, T. -C. [2 ]
Ko, J. J. [2 ]
Burton, E. [3 ]
Sasane, R. [2 ]
机构：
[1] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
[2] Novartis Pharmaceut, Hlth Econ & Outcomes Res, E Hanover, NJ USA
[3] Novartis Pharmaceut, US Med Affairs, E Hanover, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P658
引用
收藏
页码：322 / 323
页数：2
相关论文
共 50 条
  • [21] Patients' satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
    Spessotto, Caroline
    Cavalli, Hanaie
    Eboni, Audred
    Machado, Rafael
    Mousquer, Analara
    Palazzo, Lara
    Finkelsztejn, Alessandro
    Goncalves, Marcos
    Sato, Henry
    Siquineli, Fabio
    Fragoso, Yara
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 141 - 141
  • [22] Treatment Patterns in Disease-Modifying Therapy for Patients With Multiple Sclerosis in the United States
    Bonafede, Machaon M.
    Johnson, Barbara H.
    Wenten, Made
    Watson, Crystal
    CLINICAL THERAPEUTICS, 2013, 35 (10) : 1501 - 1512
  • [23] Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple Sclerosis
    Bruno, Antonio
    Annovazzi, Pietro
    Clerico, Marinella
    Cocco, Eleonora
    Conte, Antonella
    Marfia, Girolama Alessandra
    Salvetti, Marco
    Tomassini, Valentina
    Clerici, Valentina Torri
    Totaro, Rocco
    Dolcetti, Ettore
    Centonze, Diego
    CURRENT NEUROPHARMACOLOGY, 2025, 23 (05) : 503 - 510
  • [24] Patients' satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
    Spessotto, Caroline Vieira
    Cavalli, Hanaie
    Biondo Eboni, Audred Cristina
    Machado, Rafael Berlezi
    Mousquer, Analara Munardi
    Palazzo, Lara Both
    Finkelsztejn, Alessandro
    Magno Goncalves, Marcus Vinicius
    Sato, Henry Koiti
    Siquineli, Fable
    Fragoso, Yara Dadalti
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2016, 74 (08) : 617 - 620
  • [25] Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment
    Manuel Garcia-Dominguez, Jose
    Munoz, Delicias
    Comellas, Marta
    Gonzalbo, Irmina
    Lizan, Luis
    Polanco Sanchez, Carlos
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 1945 - 1956
  • [26] Multiple sclerosis relapse severity and recovery in the current disease-modifying therapy era
    Wynford-Thomas, Ray
    McNabb, Carolyn
    Cauchi, Marija
    Hawken, Jonathan
    Hu, Mo
    Simmonds, Joseph
    Thomas, Rachel
    Williams, Sioned
    Anderson, Valerie
    Loveless, Samantha
    Willis, Mark
    Pickersgill, Trevor
    Robertson, Neil
    Tallantyre, Emma
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 434 - 435
  • [27] Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
    Vartanian, TK
    Zamvil, SS
    Fox, E
    Sorensen, PS
    NEUROLOGY, 2004, 63 (11) : S42 - S49
  • [28] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272
  • [29] Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
    Grebenciucova, Elena
    Pruitt, Amy
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2017, 17 (11)
  • [30] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
12345